

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No.)*

Rennova Health, Inc.
(Name of Issuer)

Common Stock, \$0.0001 par value per share
(Title of Class of Securities)

759757875
(CUSIP Number)

Christopher E. Diamantis
1143 Glendale Lane
Nashville, Tennessee 37204

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

August 27, 2021
(Date of Event which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box .

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosure provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 759757875

13D

Page 2 of 6

1.	Names of Reporting Persons	
	Christopher E. Diamantis	
2.	Check the Appropriate Box if a Member of a Group	(a) <input type="checkbox"/> (b) <input type="checkbox"/>
3.	SEC Use Only	
4.	Source of Funds (See Instructions)	OO
5.	Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)	<input type="checkbox"/>
6.		
	Number Of Shares Beneficially Owned By Each Reporting Person With	
	7.	Sole Voting Power 95,450,000
	8.	Shared Voting Power -0-
	9.	Sole Dispositive Power 95,450,000
	10.	Shared Dispositive Power -0-
11.	Aggregate Amount Beneficially Owned by Each Reporting Person	95,450,000
12.	Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)	<input checked="" type="checkbox"/>
13.	Percent of Class Represented by Amount in Row (11)	51.24% ⁽¹⁾
14.	Type of Reporting Person	IN

⁽¹⁾ This percentage is based on 186,249,999 shares of common stock of the Issuer outstanding as of August 28, 2021.

Item 1. Security and Issuer

This Schedule 13D relates to the Common Stock, \$0.0001 par value per share (the "Common Stock"), of Rennova Health, Inc., a Delaware corporation (the "Issuer"). The principal executive offices of the Issuer are located at 400 South Australian Avenue, 8th Floor, West Palm Beach, Florida 33401.

Item 2. Identity and Background

- (a) This Schedule 13D is being filed by Christopher E. Diamantis.
- (b) The address of Mr. Diamantis is 1143 Glendale Lane, Nashville, Tennessee 37204.
- (c) Mr. Diamantis is currently a private investor.
- (d) During the last five years, Mr. Diamantis has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
- (e) During the last five years, Mr. Diamantis has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decision or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws.
- (f) Mr. Diamantis is a citizen of the United States of America.

Item 3. Source and Amount of Funds or Other Consideration

On April 27, 2021, Mr. Diamantis converted 620 shares of the Issuer's Series M Convertible Redeemable Preferred Stock (the "Series M Preferred Stock") into 450,000 shares of Common Stock. On August 27, 2021, the Issuer entered into an Exchange Agreement with Mr. Diamantis, pursuant to which Mr. Diamantis exchanged 570 shares of Series M Preferred Stock for 95,000,000 shares of Common Stock and warrants (the "Warrants") to purchase 47,500,000 shares of Common Stock. The Warrants have a three-year term, are exercisable at \$0.007 per share and are subject to customary anti-dilution protections.

Item 4. Purpose of Transaction

Mr. Diamantis has acquired, and holds, the shares of Common Stock reported herein for investment purposes. He may acquire additional shares of Common Stock depending on market conditions and the business performance of the Issuer, but does not currently plan to purchase a number of additional shares of Common Stock that would result in a substantial change in his beneficial ownership or his ability to influence control of the Issuer.

Although immediately after the Exchange Agreement, Mr. Diamantis beneficially owned approximately 51.24% of the Common Stock, he did not have voting control of the Issuer's voting securities. The Series M Preferred Stock, as a class, has the number of votes, in the aggregate, equal to 51% of all votes entitled to be voted at any meeting of stockholders or action by written consent. Mr. Diamantis does own all of the Series M Preferred Stock, but on August 13, 2020 he granted an irrevocable proxy (the "Proxy") to Seamus Lagan, the Chief Executive Officer of the Issuer, to vote the shares of Series M Preferred Stock owned by Mr. Diamantis. Mr. Diamantis retained all other rights of the Series M Preferred Stock.

On August 27, 2021, after the Exchange Agreement, Mr. Diamantis, Mr. Lagan and Alcimede LLC, of which Mr. Lagan is the sole manager, collectively the holders of approximately 78.54% of the total voting power of the Issuer's voting securities (as well as approximately 51.24% of the shares of Common Stock then outstanding), approved by written consents in lieu of a special meeting of stockholders two proposals, each of which had been previously approved and recommended to be approved by the stockholders by the Board of Directors of the Issuer:

Proposal 1: To increase the authorized shares of Common Stock of the Issuer from 10 billion shares to 50 billion shares.

Proposal 2: To allow that the authorized shares of Common Stock and Preferred Stock of the Issuer may be increased or decreased (but not below the number of shares then outstanding) by the affirmative vote of the holders of a majority in voting power of the Issuer entitled to vote generally in the election of directors, irrespective of the provisions of Section 242(b)(2) of the General Corporation Law of the State of Delaware (or any successor thereto), voting together as a single class, without a separate vote of the holders of the class or classes the number of authorized shares of which are being increased or decreased unless a vote by any holders of one or more series of Preferred Stock is required by the express terms of any series of Preferred Stock pursuant to the terms thereof.

The stockholder approval of the above proposals will not be effective until 20 days after an information statement that has been filed with the Securities and Exchange Commission is mailed to the holders of the Common Stock and the Series F Convertible Preferred Stock of the Issuer.

Other than as described above, and except that Mr. Diamantis may, from time to time or at any time, subject to market conditions and other factors and subject to the Lock-Up Agreement described in Item 6 below, purchase additional shares of Common Stock in the open market, in privately negotiated transactions or otherwise, sell at any time all or a portion of the shares of Common Stock now owned or hereafter acquired by him to one or more purchasers, or transfer or contribute shares of Common Stock to trusts for estate planning purposes, Mr. Diamantis does not have any present plans which relate to or would result in:

- (a) the acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer;
- (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries;
- (c) a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries;
- (d) any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;
- (e) any material change in the present capitalization or dividend policy of the Issuer;

- (f) any other material change in the Issuer's business or corporate structure;
- (g) changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person;
- (h) causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;
- (i) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Exchange Act; or
- (j) any action similar to any of those actions enumerated above.

CUSIP No. 759757875

13D

Page 5 of 6

Item 5. Interest in Securities of the Issuer

As of August 27, 2021, Mr. Diamantis may be deemed to beneficially own 95,450,000 shares of Common Stock (or approximately 51.24% of the total number of shares then outstanding). All of such shares are owned of record by Mr. Diamantis. Mr. Diamantis also owned, as of August 27, 2021, 20,810 shares of Series M Preferred Stock and the Warrants to purchase 47,500,000 shares of Common Stock. The Series M Preferred Stock and the Warrants, however, are each subject to a beneficial ownership limitation of 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of the shares of Common Stock issuable upon conversion or exercise, as the case may be. As a result, the Series M Preferred Stock and the Warrants owned by Mr. Diamantis are not convertible or exercisable into shares of Common Stock as of August 27, 2021. In addition, on August 13, 2020 Mr. Diamantis granted the Proxy to Mr. Lagan, the Chief Executive Officer of the Issuer, to vote the shares of Series M Preferred Stock owned by Mr. Diamantis. No shares of Common Stock into which the Series M Preferred Stock or Warrants would otherwise be convertible or exercisable and none of the rights to vote the Series M Preferred Stock are included in Mr. Diamantis' beneficial ownership as reflected in this Schedule 13D.

The only transaction by Mr. Diamantis in the securities of the Issuer in the 60 days preceding the filing of this Schedule was the exchange of shares of Series M Preferred Stock for shares of Common Stock and the Warrants pursuant to the Exchange Agreement, as discussed above.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

In addition to the Exchange Agreement, Mr. Diamantis is also party to the Lock-Up Agreement, dated May 10, 2021, with the Issuer (the "Lock-Up Agreement"). Under the Lock-Up Agreement, Mr. Diamantis agreed that, until the date the Issuer amends its Certificate of Incorporation to increase its authorized shares of Common Stock to at least 50 billion shares, he will not offer, sell, exercise, convert, contract to sell, hypothecate, pledge or otherwise dispose (or enter into any transaction which is designed to, or might reasonably be expected to, result in the disposition by him or any affiliate) of any shares of Common Stock (except for the 450,000 shares he acquired on April 27, 2021).

The foregoing descriptions of the Exchange Agreement and the Lock-Up Agreement do not purport to be complete and are qualified by reference to the full texts of the Exchange Agreement and the Lock-Up Agreement, copies of which are filed as exhibits to this Schedule 13D and incorporated herein by reference.

Item 7. Materials to be Filed as Exhibits

[Exhibit 1: Exchange Agreement, dated as of August 27, 2021, between Rennova Health, Inc. and Christopher E. Diamantis \(incorporated by reference to Exhibit 10.1 of the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 2, 2021\).](#)

[Exhibit 2: Lock-Up Agreement, dated May 10, 2021, between Christopher E. Diamantis and Rennova Health, Inc. \(filed herewith\).](#)

CUSIP No. 759757875

13D

Page 6 of 6

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

September 27, 2021

/s/ Christopher E. Diamantis
Christopher E. Diamantis

LOCK-UP AGREEMENT

May 10, 2021

Re: Securities Purchase Agreement, dated as of May 10, 2021 (the "Purchase Agreement"), by and between Rennova Health, Inc., a Delaware corporation (the "Company"), and the purchasers signatory thereto (each, a "Purchaser" and, collectively, the "Purchasers")

Ladies and Gentlemen:

This letter agreement (the "Letter Agreement") is entered into pursuant to Section 2.2(a)(iv) of the Purchase Agreement and in satisfaction of a condition of the Company's obligations under the Purchase Agreement. The undersigned irrevocably agrees with the Company that, from the date hereof until the date that the Company amends its Certificate of Incorporation to increase its authorized shares of common stock to at least 50 billion shares (such period, the "Restriction Period"), the undersigned will not offer, sell, exercise, convert, contract to sell, hypothecate, pledge or otherwise dispose of (or enter into any transaction which is designed to, or might reasonably be expected to, result in the disposition (whether by actual disposition or effective economic disposition due to cash settlement or otherwise) by the undersigned or any Affiliate (as defined in the Purchase Agreement) of the undersigned or any person in privity with the undersigned or any Affiliate of the undersigned), directly or indirectly, or establish or increase a put equivalent position or liquidate or decrease a call equivalent position within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), with respect to, any shares of common stock of the Company or securities convertible, exchangeable or exercisable into, shares of common stock of the Company beneficially owned, held or hereafter acquired by the undersigned (the "Securities"). Beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act. In order to enforce this covenant, the Company (i) shall impose irrevocable stop-transfer instructions preventing the transfer agent of the Company from effecting any actions in violation of this Letter Agreement and (ii) shall not effect any exercise or conversion of any Securities. Notwithstanding the foregoing, if (i) the Company issues an earnings release or material news, or a material event relating to the Company occurs, during the last 17 days of the Restriction Period, or (ii) prior to the expiration of the Restriction Period, the Company announces that it will release earnings results during the 16-day period beginning on the last day of the Restriction Period, the restrictions imposed by this Letter Agreement shall continue to apply until the expiration of the 18-day period beginning on the issuance of the earnings release or the occurrence of the material news or material event, unless the Company and the Purchasers waive such extension.

Notwithstanding anything herein to the contrary, this Letter Agreement shall not be applicable to or restrict in any way the 450 million shares of common stock issued to the undersigned upon his conversion of shares of Series M Convertible Preferred Stock and such shares of common stock shall not be Securities hereunder.

The undersigned acknowledges that the execution, delivery and performance of this Letter Agreement is a material inducement to each Purchaser to complete the transactions contemplated by the Purchase Agreement and that each Purchaser (which shall be a third-party beneficiary of this Letter Agreement) and the Company shall be entitled to specific performance of the undersigned's obligations hereunder. The undersigned hereby represents that the undersigned has the power and authority to execute, deliver and perform this Letter Agreement, that the undersigned has received adequate consideration therefor and that the undersigned will indirectly benefit from the closing of the transactions contemplated by the Purchase Agreement.

This Letter Agreement may not be amended or otherwise modified in any respect without the written consent of each of the Company, each Purchaser and the undersigned. This Letter Agreement shall be construed and enforced in accordance with the laws of the State of New York without regard to the principles of conflict of laws. The undersigned hereby irrevocably submits to the exclusive jurisdiction of the United States District Court sitting in the Southern District of New York and the courts of the State of New York located in Manhattan, for the purposes of any suit, action or proceeding arising out of or relating to this Letter Agreement, and hereby waives, and agrees not to assert in any such suit, action or proceeding, any claim that (i) he is not personally subject to the jurisdiction of such court, (ii) the suit, action or proceeding is brought in an inconvenient forum, or (iii) the venue of the suit, action or proceeding is improper. The undersigned hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by receiving a copy thereof sent to the Company at the address in effect for notices to it under the Purchase Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. The undersigned hereby waives any right to a trial by jury.

Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. The undersigned agrees and understands that this Letter Agreement does not intend to create any relationship between the undersigned and each Purchaser and that each Purchaser is not entitled to cast any votes on the matters herein contemplated and that no issuance or sale of the Securities is created or intended by virtue of this Letter Agreement.

By its signature below, the Company hereby acknowledges and agrees that, reflecting this Letter Agreement, it has placed an irrevocable stop transfer instruction on all Securities beneficially owned by the undersigned until the end of the Restriction Period. This Letter Agreement shall be binding on successors and assigns of the undersigned with respect to the Securities and any such successor or assign shall enter into a similar agreement for the benefit of the Purchasers.

*** SIGNATURE PAGE FOLLOWS***

This Letter Agreement may be executed in two or more counterparts, all of which when taken together may be considered one and the same agreement.

/s/ Christopher E. Diamantis
Signature

Christopher E. Diamantis
Print Name

Address for Notice:

Number of shares of Common Stock

Number of shares of Common Stock underlying subject to warrants, options, debentures or other convertible securities

By signing below, the Company agrees to enforce the restrictions on transfer set forth in this Letter Agreement.

By: /s/ Seamus Lagan
Name: Seamus Lagan
Title: CEO